论文部分内容阅读
随着免疫化学、分子生物学及基因工程技术发展,借助于基因克隆技术或亚结构移植技术,可生产大量高纯度的淋巴/细胞因子,使其在实验与临床的广泛应用成为可能。初步结果表明,为数众多的淋巴/细胞因子研究不仅有重大理论意义,而且其临床应用已大大开拓了现代医学诊疗的新里程,兹简介如下。一、淋巴/细胞因子的由来与认识Bloom 和Bennett(1966)最先证实,经抗原激活淋巴细胞能产生一类可溶性、非抗体的生物学反应调节物质,调节机体迟发性过敏反应。继而,David 发现这类物质在所有细胞介导的免疫反应中起调节作用并命名为淋巴因子
With the development of immunochemistry, molecular biology and genetic engineering technology, a large number of high-purity lymphocytes/cytokines can be produced by means of gene cloning technology or substructure transplantation technology, making it possible to be widely used in experiments and clinical applications. The preliminary results indicate that a large number of lymphatic/cytokine researches have not only theoretical significance, but also their clinical application has greatly expanded the new milestones of modern medical treatment. First, the origin and understanding of lymphatic / cytokines Bloom and Bennett (1966) was the first to confirm that antigen activated lymphocytes can produce a class of soluble, non-antibody biological response regulators that regulate late-onset allergic reactions. In turn, David found that these substances play a regulatory role in all cell-mediated immune responses and were named lymphokines.